Immunogenicity of anti-TNF antibodies. Has the veil been lifted?
Abstract
No abstract availableKeywords
This publication has 14 references indexed in Scilit:
- Clinical Utility of Measuring Infliximab and Human Anti-Chimeric Antibody Concentrations in Patients With Inflammatory Bowel DiseaseAmerican Journal of Gastroenterology, 2010
- Influence of Trough Serum Levels and Immunogenicity on Long-term Outcome of Adalimumab Therapy in Crohn's DiseaseGastroenterology, 2009
- Monitoring patients treated with anti-TNF- biopharmaceuticals: assessing serum infliximab and anti-infliximab antibodiesRheumatology, 2007
- Association of Trough Serum Infliximab to Clinical Outcome After Scheduled Maintenance Treatment for Crohn’s DiseaseClinical Gastroenterology and Hepatology, 2006
- Immunogenicity of engineered antibodiesMethods, 2005
- Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn’s diseaseClinical Gastroenterology and Hepatology, 2004
- Erythropoiesis-stimulating agents and antibody-mediated pure red-cell aplasia: here are we now and where do we go from here?Nephrology Dialysis Transplantation, 2004
- Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: A randomized controlled trialGastroenterology, 2003
- Influence of Immunogenicity on the Long-Term Efficacy of Infliximab in Crohn's DiseaseNew England Journal of Medicine, 2003
- The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis: Results from ATTRACT, a multicenter, randomized, double‐blind, placebo‐controlled trialArthritis & Rheumatism, 2002